The renin angiotensin system in Alzheimer’s disease – the missing link between cardiovascular-disease mediated risk in Alzheimer’s disease?

6 March 2018, 1.00 PM - 6 March 2018, 2.00 PM

Professor Patrick Kehoe, Bristol Medical School, Translational Health Sciences

BG10, Oakfield House, Oakfield Grove, Bristol, BS8 2BN.

Dementia is one of the largest healthcare concerns of our time and Alzheimer's disease (AD), the most common form, is a complex insidious disorder with multiple causes of neuropathology. Many therapeutic strategies to treat AD to date have focussed on symptoms, but more recently there has been movement towards attempts at disease modification through focus on molecular targets or processes that initiate the disease or exacerbate the course of progression. Poly pharmacy has been proposed to be a possible solution to properly tackle the complexities of AD and yet multifunctional targets or pathways could offer similar benefit whilst reducing the likely consequences and adverse effects that come with polypharmacy, particularly amongst elderly populations. How a centrally acting Renin Angiotensin System could hold clues to a number of the neuropathological and clinical complexities of AD will be discussed that in themselves will be shown to fortuitously offer themselves towards future clinical trials and potentially highly economical options to enrich a limited and currently stagnant therapeutic landscape for Alzheimer’s disease.  
Professor Pat Kehoe, who gained his BSc in Pharmacology and Molecular Genetics from UCD and his PhD on the Molecular Genetics of Alzheimer’s disease from Cardiff University, is the Gestetner Professor of Translational Dementia Research at the University of Bristol. He is a member of the Research Strategy Committee for the UK Alzheimer’s Society, is a member of the Executive Committee of the European Alzheimer’s disease Consortium and has over 170 publications to date. As part of his PhD studies he discovered variation in the ACE gene to be a risk factor for Alzheimer’s disease, which set him on a path to study the role of the renin angiotensin system (RAS) in Alzheimer’s disease (AD). The work of his group of the role of RAS in AD over the last 15 years has helped to unveil its prominence in a number of pathological processes in AD and in doing so may help explain some of the longheld recognition but limited understanding of associations between blood pressure regulation and the development and progression of dementia, particularly AD. Over the last decade he has established himself as a leading name in this emerging field and some of his pre-clinical and pharmacoepidemiology work has now informed the basis of a number of drug repurposing clinical trials of RAS-acting drugs in Alzheimer's disease, one of the largest of which, the RADAR Trial that will complete in Summer 2019, he leads as Chief Investigator.

Contact information

No booking required, all welcome.

Edit this page